We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: immunogenicity
MedXY News
EnglishTag

immunogenicity

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Immunogenicity and Safety of Pentavalent Meningococcal MenABCWY Vaccine in Adolescents and Young Adults: Integrated Evidence from Late-Phase Clinical Trials
Clinical Updatesmeningococcal diseaseMenABCWY vaccine

Immunogenicity and Safety of Pentavalent Meningococcal MenABCWY Vaccine in Adolescents and Young Adults: Integrated Evidence from Late-Phase Clinical Trials

By MedXY|Sep 4, 2026

This review synthesizes phase 2 and 3 trial data demonstrating that the pentavalent MenABCWY vaccine is immunologically non-inferior and well tolerated compared with MenB-fHbp and MenACWY-CRM vaccines, offering a simplified, effective vacci

DR5/Ligase 3 Feedback Loop: Unlocking the Immunogenicity of Mismatch Repair-Deficient Colorectal Cancer
Gastroenterology
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
colorectal cancer
immune checkpoint inhibitors

DR5/Ligase 3 Feedback Loop: Unlocking the Immunogenicity of Mismatch Repair-Deficient Colorectal Cancer

By MedXY|Jul 20, 2026

This study uncovers a novel DR5/Ligase 3 feedback mechanism that sustains immunogenicity and enhances immune checkpoint inhibitor response in mismatch repair-deficient colorectal cancer.

Two-Dose HeV-sG-V Regimen Demonstrates Robust Neutralizing Antibody Response Against Nipah Virus in Phase 1 Trial
Infectious Diseasesimmunogenicityinfectious diseases

Two-Dose HeV-sG-V Regimen Demonstrates Robust Neutralizing Antibody Response Against Nipah Virus in Phase 1 Trial

By MedXY|Jan 14, 2026

A Phase 1 trial confirms that the HeV-sG-V vaccine is safe and, when administered in a two-dose 100 μg regimen, induces high levels of neutralizing antibodies against both Bangladesh and Malaysia strains of the Nipah virus.

Novel Type 1 and Type 3 Live Attenuated Oral Poliovirus Vaccines Show Comparable Safety, Immunogenicity, and Shedding to Sabin mOPV in First‑in‑Human Phase 1 Trial
Infectious Diseasesimmunogenicity

Novel Type 1 and Type 3 Live Attenuated Oral Poliovirus Vaccines Show Comparable Safety, Immunogenicity, and Shedding to Sabin mOPV in First‑in‑Human Phase 1 Trial

By MedXY|Dec 1, 2025

A multicentre phase 1 trial in healthy US adults found nOPV1 and nOPV3 were well tolerated and induced robust homotypic neutralising antibody responses with shedding profiles similar to Sabin monovalent OPV, supporting progression to phase

EuTCV Vi‑CRM197 (Single‑ and Multidose) Is Non‑Inferior to Typbar TCV in Infants and Well Tolerated Across Age Groups in Kenya and Senegal
Infectious Diseasesimmunogenicityphase 3 trial

EuTCV Vi‑CRM197 (Single‑ and Multidose) Is Non‑Inferior to Typbar TCV in Infants and Well Tolerated Across Age Groups in Kenya and Senegal

By MedXY|Nov 30, 2025

A multicentre phase 3 trial shows single‑ and multidose EuTCV (Vi‑CRM197) are immunologically non‑inferior to Typbar TCV in infants 9–12 months, with comparable safety and reactogenicity across ages — supporting WHO prequalification.

Immunogenicity and HPV Infection After One, Two, and Three Doses of Quadrivalent HPV Vaccine in Indian Girls: A Multicentre Prospective Cohort Study
Infectious Diseasescervical cancer preventionHPV vaccine

Immunogenicity and HPV Infection After One, Two, and Three Doses of Quadrivalent HPV Vaccine in Indian Girls: A Multicentre Prospective Cohort Study

By MedXY|Nov 24, 2025

This study evaluates immune responses and HPV infection rates in Indian girls after receiving one, two, or three doses of the quadrivalent HPV vaccine, supporting WHO’s recommendation for two doses spaced at least six months apart.

A Single Shot Against Rift Valley Fever? Phase 1 ChAdOx1 RVF Trial Shows Acceptable Safety and Robust Immune Responses in Uganda
Infectious DiseasesimmunogenicityVaccine

A Single Shot Against Rift Valley Fever? Phase 1 ChAdOx1 RVF Trial Shows Acceptable Safety and Robust Immune Responses in Uganda

By MedXY|Nov 23, 2025

In a randomized, placebo-controlled phase 1 trial in Uganda, a single intramuscular dose of ChAdOx1 RVF (adenovirus-vectored) was well tolerated and induced rapid T-cell responses and neutralising antibodies, supporting further evaluation o

rVSVΔG‑LASV‑GPC Lassa Vaccine Shows Broad Immunogenicity and Acceptable Safety in Phase 1 Trial
Infectious Diseasesimmunogenicitysafety

rVSVΔG‑LASV‑GPC Lassa Vaccine Shows Broad Immunogenicity and Acceptable Safety in Phase 1 Trial

By MedXY|Nov 10, 2025

A phase 1 trial of the rVSV‑vectored Lassa vaccine demonstrated dose-dependent transient reactogenicity, no vaccine‑related serious adverse events or hearing loss, and robust, durable humoral and cellular responses across doses and lineages

Boosting Immunity Against Group B Streptococcus: Safety and Efficacy of a Novel Hexavalent Conjugate Vaccine Booster in Healthy Adults
Infectious Diseasesimmunogenicity

Boosting Immunity Against Group B Streptococcus: Safety and Efficacy of a Novel Hexavalent Conjugate Vaccine Booster in Healthy Adults

By MedXY|Oct 31, 2025

A booster dose of the hexavalent group B streptococcus conjugate vaccine (GBS6) administered approximately two years after the primary dose in healthy adults is safe and elicits robust, enhanced immune responses, promising for maternal immu

Breakthrough in Enteric Fever Prevention: Efficacy and Safety of the Novel Salmonella Paratyphi A Vaccine CVD 1902
Infectious Diseasesimmunogenicitylive-attenuated vaccine

Breakthrough in Enteric Fever Prevention: Efficacy and Safety of the Novel Salmonella Paratyphi A Vaccine CVD 1902

By MedXY|Oct 31, 2025

A novel live attenuated oral vaccine, CVD 1902, shows 73% efficacy against Salmonella Paratyphi A infection in a controlled human challenge model, offering promising protection with a favorable safety profile.

Evaluating the Safety and Immunogenicity of the Adjuvanted RSVPreF3 Vaccine in High-Risk Transplant Recipients: A Critical Analysis of an Interventional Cohort Study
Infectious DiseasesimmunogenicityRSV vaccine

Evaluating the Safety and Immunogenicity of the Adjuvanted RSVPreF3 Vaccine in High-Risk Transplant Recipients: A Critical Analysis of an Interventional Cohort Study

By MedXY|Oct 6, 2025

This study assesses the safety and immune response of an adjuvanted RSVPreF3 vaccine in adult allogeneic hematopoietic cell and lung transplant recipients, highlighting modest antibody responses but robust CD4+ T-cell activation, supporting

Promising Immunogenicity and Safety of the Live-Attenuated Intranasal RSV Vaccine in Infants and Toddlers
Pediatricsimmunogenicityinfants

Promising Immunogenicity and Safety of the Live-Attenuated Intranasal RSV Vaccine in Infants and Toddlers

By MedXY|Oct 5, 2025

This phase I/II trial demonstrates that the live-attenuated intranasal RSV vaccine (RSVt) is immunogenic and well-tolerated in infants and toddlers, offering a potential new preventive option against RSV infection.

M72/AS01E-4 Tuberculosis Vaccine: Promising Advances for HIV-Positive Populations in High-Burden Settings
Clinical UpdatesHIVimmunogenicity

M72/AS01E-4 Tuberculosis Vaccine: Promising Advances for HIV-Positive Populations in High-Burden Settings

By MedXY|Oct 1, 2025

A phase 2 trial in South Africa shows that the M72/AS01E-4 TB vaccine is safe and immunogenic for virally suppressed, ART-treated HIV-positive adolescents and adults, supporting its potential to address a key unmet clinical need.

Impact of Maternal Pertussis Vaccination on Infant Immune Responses: Insights from the GaPS Trial in The Gambia
Clinical Updatesimmunogenicitypertussis

Impact of Maternal Pertussis Vaccination on Infant Immune Responses: Insights from the GaPS Trial in The Gambia

By MedXY|Oct 1, 2025

A phase 4 trial in The Gambia finds that maternal Tdap-IPV vaccination is safe and provides early infant protection, but modestly blunts immune responses to whole-cell pertussis vaccines without compromising overall immunogenicity.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities